MA31606B1 - Anticorps anti-cd 79b immunoconjugues et procedes d'utilisation - Google Patents

Anticorps anti-cd 79b immunoconjugues et procedes d'utilisation

Info

Publication number
MA31606B1
MA31606B1 MA32613A MA32613A MA31606B1 MA 31606 B1 MA31606 B1 MA 31606B1 MA 32613 A MA32613 A MA 32613A MA 32613 A MA32613 A MA 32613A MA 31606 B1 MA31606 B1 MA 31606B1
Authority
MA
Morocco
Prior art keywords
methods
immunoconjugated antibodies
immunoconjugated
antibodies
mammals
Prior art date
Application number
MA32613A
Other languages
English (en)
Inventor
Yvonne Chen
Mark Dennis
David Dornan
Kristi Elkins
Jagath Reddy Junutula
Andrew Polson
Bing Zheng
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39929686&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA31606(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of MA31606B1 publication Critical patent/MA31606B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/537—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines spiro-condensed or forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68031—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being an auristatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68033—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a maytansine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6867—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from a cell of a blood cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1027—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3061—Blood cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/5759—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds localised on the membrane of tumour or cancer cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70596—Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • Urology & Nephrology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Optics & Photonics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)

Abstract

LA PRÉSENTE INVENTION CONCERNE DES COMPOSITIONS DE PRODUITS CONVENANT AU TRAITEMENT DE TUMEUR HÉMATOPOÏÉTIQUE CHEZ LES MAMMIFÈRES, ET DES PROCÉDÉS D'UTILISATION DE CES COMPOSITIONS À CET EFFET.
MA32613A 2007-07-16 2010-02-11 Anticorps anti-cd 79b immunoconjugues et procedes d'utilisation MA31606B1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US95005207P 2007-07-16 2007-07-16
US2513708P 2008-01-31 2008-01-31
US3279008P 2008-02-29 2008-02-29
US5470908P 2008-05-20 2008-05-20

Publications (1)

Publication Number Publication Date
MA31606B1 true MA31606B1 (fr) 2010-08-02

Family

ID=39929686

Family Applications (1)

Application Number Title Priority Date Filing Date
MA32613A MA31606B1 (fr) 2007-07-16 2010-02-11 Anticorps anti-cd 79b immunoconjugues et procedes d'utilisation

Country Status (39)

Country Link
US (7) US8088378B2 (fr)
EP (3) EP2176296B1 (fr)
JP (3) JP5469600B2 (fr)
KR (2) KR101486615B1 (fr)
CN (4) CN101802012B (fr)
AR (1) AR067544A1 (fr)
AT (1) ATE543835T1 (fr)
AU (1) AU2008276140C1 (fr)
BR (2) BR122022005321B1 (fr)
CA (3) CA3160831A1 (fr)
CL (1) CL2008002085A1 (fr)
CO (1) CO6270252A2 (fr)
CR (3) CR20190516A (fr)
CY (3) CY1112739T1 (fr)
DK (2) DK2474557T3 (fr)
EC (1) ECSP109878A (fr)
ES (3) ES2579323T3 (fr)
FR (1) FR20C1033I2 (fr)
HR (2) HRP20120352T1 (fr)
HU (1) HUS2000026I1 (fr)
IL (3) IL203142A (fr)
LT (1) LTC2474557I2 (fr)
MA (1) MA31606B1 (fr)
MY (1) MY150531A (fr)
NL (1) NL301056I1 (fr)
NO (1) NO2020020I1 (fr)
NZ (2) NZ583367A (fr)
PE (2) PE20140614A1 (fr)
PH (2) PH12013501338A1 (fr)
PL (2) PL2474557T3 (fr)
PT (2) PT2474557E (fr)
RS (2) RS53595B1 (fr)
RU (2) RU2511410C3 (fr)
SG (2) SG183023A1 (fr)
SI (2) SI2474557T1 (fr)
TW (2) TWI392503B (fr)
UA (1) UA116618C2 (fr)
WO (1) WO2009012268A1 (fr)
ZA (1) ZA201000080B (fr)

Families Citing this family (139)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2749110B2 (ja) 1989-03-24 1998-05-13 住友スリーエム株式会社 電力ケーブルの耐火接続部
US20110045005A1 (en) 2001-10-19 2011-02-24 Craig Crowley Compositions and methods for the treatment of tumor of hematopoietic origin
US20090068178A1 (en) * 2002-05-08 2009-03-12 Genentech, Inc. Compositions and Methods for the Treatment of Tumor of Hematopoietic Origin
US20100111856A1 (en) * 2004-09-23 2010-05-06 Herman Gill Zirconium-radiolabeled, cysteine engineered antibody conjugates
US8168181B2 (en) * 2006-02-13 2012-05-01 Alethia Biotherapeutics, Inc. Methods of impairing osteoclast differentiation using antibodies that bind siglec-15
CA2822302A1 (fr) 2006-02-13 2007-08-23 Alethia Biotherapeutics Inc. Procedes pour alterer la differenciation osteoclaste
US7919092B2 (en) 2006-06-13 2011-04-05 Oncomed Pharmaceuticals, Inc. Antibodies to notch receptors
EP2125887A4 (fr) 2007-01-24 2010-11-10 Oncomed Pharm Inc Compositions et procedes utilises pour le diagnostic et le traitement du cancer
DK2474557T3 (da) 2007-07-16 2014-11-10 Genentech Inc Anti-CD79b-antistoffer og immunkonjugater og fremgangsmåder til anvendelse
NZ583318A (en) 2007-07-16 2012-07-27 Genentech Inc Humanized anti-cd79b antibodies and immunoconjugates and methods of use
MX2010003718A (es) * 2007-10-19 2010-04-21 Genentech Inc Anticuerpos anti-tenb2 producidos por ingenieria de cisteina y conjugados de farmaco y anticuerpo.
SG187517A1 (en) * 2008-01-31 2013-02-28 Genentech Inc Anti-cd79b antibodies and immunoconjugates and methods of use
US20100092495A1 (en) * 2008-04-30 2010-04-15 Immunogen Inc. Potent cell-binding agent drug conjugates
US9132189B2 (en) 2008-07-08 2015-09-15 Oncomed Pharmaceuticals, Inc. Notch1 binding agents and methods of use thereof
CN104402998A (zh) 2008-07-08 2015-03-11 昂考梅德药品有限公司 分离的抗体
WO2010126552A1 (fr) * 2009-04-30 2010-11-04 Immunogen, Inc. Conjugués de médicament d'agent de liaison cellulaire puissant
US8404811B2 (en) 2009-05-08 2013-03-26 Genentech, Inc. Humanized anti-EGFL7 antibodies and methods using same
JP2012531212A (ja) * 2009-07-03 2012-12-10 アビペップ ピーティーワイ リミテッド イムノコンジュゲート及びその作製方法
SI2454284T1 (en) 2009-07-15 2018-07-31 Aimm Therapeutics B.V. Compounds that specifically bind to Gram-positive bacteria
SG181814A1 (en) 2009-12-23 2012-07-30 Avipep Pty Ltd Immuno-conjugates and methods for producing them 2
MX2012008085A (es) * 2010-01-13 2012-09-12 Oncomed Pharm Inc Agentes de union notch1 y metodos de uso de los mismos.
JP5767207B2 (ja) 2010-03-26 2015-08-19 協和発酵キリン株式会社 新規修飾部位導入抗体および抗体フラグメント
BR112012030311A2 (pt) 2010-06-08 2017-01-24 Genentech Inc anticorpo
AU2011316917B2 (en) 2010-10-22 2016-02-25 Seagen Inc. Synergistic effects between auristatin-based antibody drug conjugates and inhibitors of the PI3K-AKT mTOR pathway
US20130101628A1 (en) * 2011-04-29 2013-04-25 Northwestern University Novel vegf mimetic peptide-based scaffolds for therapeutic angiogenesis and methods for their use
SG11201400859SA (en) 2011-09-22 2014-04-28 Amgen Inc Cd27l antigen binding proteins
CA2853138A1 (fr) 2011-12-05 2013-06-13 Immunomedics, Inc. Utilisation therapeutique d'anticorps anti-cd22 pour induire une trogocytose
US9764038B2 (en) * 2011-12-23 2017-09-19 Innate Pharma Enzymatic conjugation of antibodies
AR091069A1 (es) 2012-05-18 2014-12-30 Amgen Inc Proteinas de union a antigeno dirigidas contra el receptor st2
KR20150030698A (ko) * 2012-07-09 2015-03-20 제넨테크, 인크. 항-cd79b 항체를 포함하는 면역접합체
IN2014DN10510A (fr) 2012-07-09 2015-08-21 Genentech Inc
EP2869851A1 (fr) 2012-07-09 2015-05-13 Genentech, Inc. Immunoconjugués comprenant des anticorps anti-cd22
US20140030280A1 (en) 2012-07-09 2014-01-30 Genentech, Inc. Anti-cd79b antibodies and immunoconjugates
WO2014009426A2 (fr) 2012-07-13 2014-01-16 Innate Pharma Criblage d'anticorps conjugués
US9493562B2 (en) 2012-07-19 2016-11-15 Alethia Biotherapeutics Inc. Anti-Siglec-15 antibodies
CN104870475B (zh) 2012-10-25 2019-11-08 美国比奥维拉迪维股份有限公司 抗补体C1s抗体和其用途
DK2914291T3 (da) 2012-11-02 2022-05-16 Bioverativ Usa Inc Anti-komplement-c1s-antistoffer og anvendelser deraf
US10036010B2 (en) 2012-11-09 2018-07-31 Innate Pharma Recognition tags for TGase-mediated conjugation
HUE033369T2 (en) * 2012-11-20 2017-11-28 Sanofi Sa Anti-ceacam5 antibodies and uses thereof
WO2014089177A2 (fr) 2012-12-04 2014-06-12 Massachusetts Institute Of Technology Composés, conjugués et compositions d'épipolythiodicétopipérazines et de polythiodicétopipérazines
TW201425336A (zh) 2012-12-07 2014-07-01 Amgen Inc Ｂｃｍａ抗原結合蛋白質
EP2948478B1 (fr) 2013-01-25 2019-04-03 Amgen Inc. Anticorps ciblant cdh19 pour un mélanome
KR102447350B1 (ko) * 2013-02-08 2022-09-23 노파르티스 아게 면역접합체의 제조를 위한 항체의 변형에 사용되는 특정 부위
WO2014134486A2 (fr) * 2013-02-28 2014-09-04 Immunogen, Inc. Conjugués comprenant des agents de liaison cellulaire (cba) et des agents cytotoxiques
EP2968582B1 (fr) 2013-03-15 2020-07-01 Innate Pharma Conjugaison d'anticorps en phase solide médiée par la tgase
DK2992016T3 (en) * 2013-05-02 2018-01-02 Hoffmann La Roche Combination therapy of an afucosylated CD20 antibody with a CD79b antibody-drug conjugate
SI3456743T1 (sl) 2013-05-30 2022-01-31 Kiniksa Pharmaceuticals, Ltd. Proteini, ki vežejo antigen receptorja onkostatina M
EP3010547B1 (fr) 2013-06-20 2021-04-21 Innate Pharma Conjugaison enzymatique de polypeptides
JP6744212B2 (ja) 2013-06-21 2020-08-19 イナート・ファルマ・ソシエテ・アノニムＩｎｎａｔｅ Ｐｈａｒｍａ Ｐｈａｒｍａ Ｓ．Ａ． ポリペプチドの酵素的結合
KR101899306B1 (ko) 2013-07-03 2018-10-04 서울대학교산학협력단 시스테인으로 변형된 닭의 항체 및 이를 이용한 부위-특이적 접합
TW201605896A (zh) 2013-08-30 2016-02-16 安美基股份有限公司 Gitr抗原結合蛋白
GB201409558D0 (en) 2014-05-29 2014-07-16 Ucb Biopharma Sprl Method
GB201412658D0 (en) 2014-07-16 2014-08-27 Ucb Biopharma Sprl Molecules
GB201412659D0 (en) 2014-07-16 2014-08-27 Ucb Biopharma Sprl Molecules
CN106536540A (zh) * 2014-07-24 2017-03-22 基因泰克公司 将试剂缀合至含有至少一个三硫键的蛋白质中的巯基部分的方法
MA40321A (fr) 2014-08-06 2021-04-14 Astellas Pharma Inc Nouvelle anticorp anti-ig(beta) humain
TW201609152A (zh) 2014-09-03 2016-03-16 免疫原公司 包含細胞結合劑及細胞毒性劑之偶聯物
MX2017003123A (es) 2014-09-12 2017-05-12 Genentech Inc Anticuerpos y conjugados modificados geneticamente con cisteina.
PT3262071T (pt) 2014-09-23 2020-06-16 H Hoffnabb La Roche Ag Métodos de utilização de imunoconjugados anti-cd79b
GB201419108D0 (en) * 2014-10-27 2014-12-10 Glythera Ltd Materials and methods relating to linkers for use in antibody drug conjugates
MA40938A (fr) 2014-12-05 2017-10-11 Hoffmann La Roche Anticorps anti-cd79b et méthodes d'utilisation desdits anticorps
WO2016164358A1 (fr) 2015-04-06 2016-10-13 True North Therapeutics, Inc. Anticorps anti-c1s humanisés et leurs procédés d'utilisation
CN108064246A (zh) 2015-06-15 2018-05-22 基因泰克公司 抗体和免疫结合物
GB201601073D0 (en) 2016-01-20 2016-03-02 Ucb Biopharma Sprl Antibodies
GB201601075D0 (en) * 2016-01-20 2016-03-02 Ucb Biopharma Sprl Antibodies molecules
GB201601077D0 (en) 2016-01-20 2016-03-02 Ucb Biopharma Sprl Antibody molecule
CA2997444A1 (fr) 2015-09-29 2017-04-06 Amgen Inc. Inhibiteur d'asgr destine a reduire les taux de cholesterol
AR106188A1 (es) 2015-10-01 2017-12-20 Hoffmann La Roche Anticuerpos anti-cd19 humano humanizados y métodos de utilización
CN105274116B (zh) * 2015-10-21 2020-09-29 重庆金迈博生物科技有限公司 一种制备人源化抗体的核酸分子及其应用
GB201521391D0 (en) 2015-12-03 2016-01-20 Ucb Biopharma Sprl Antibodies
GB201521382D0 (en) 2015-12-03 2016-01-20 Ucb Biopharma Sprl Antibodies
GB201521383D0 (en) 2015-12-03 2016-01-20 Ucb Biopharma Sprl And Ucb Celltech Method
GB201521389D0 (en) 2015-12-03 2016-01-20 Ucb Biopharma Sprl Method
GB201521393D0 (en) 2015-12-03 2016-01-20 Ucb Biopharma Sprl Antibodies
US10918627B2 (en) 2016-05-11 2021-02-16 Massachusetts Institute Of Technology Convergent and enantioselective total synthesis of Communesin analogs
HUE073475T2 (hu) 2016-10-12 2026-01-28 Bioverativ Usa Inc C1s elleni antitestek és alkalmazási eljárásaik
WO2018093821A1 (fr) 2016-11-15 2018-05-24 Genentech, Inc. Dosage pour le traitement avec des anticorps bispécifiques anti-cd20/anti-cd3
WO2018209239A1 (fr) 2017-05-11 2018-11-15 Massachusetts Institute Of Technology Dérivés d'agélastatine puissants en tant que modulateurs de l'invasion et de la métastase du cancer
DE102017004751A1 (de) * 2017-05-18 2018-11-22 Forschungszentrum Jülich GmbH Pyruvatcarboxylase und für die Pyruvatcarboxylase kodierende DNA, Plasmid enthaltend die DNA, sowie Mikroorganismus zur Produktion und verfahren zur Herstellung von Produkten, deren Bioynthese Oxalacetat als Vorstufe beeinhaltet und Chromosom
CA3063169A1 (fr) * 2017-06-07 2018-12-13 The General Hospital Corporation Lymphocytes t exprimant un recepteur d'antigene chimerique
WO2019057772A1 (fr) 2017-09-19 2019-03-28 Paul Scherrer Institut Procédé de conjugaison d'une transglutaminase et séquence de liaison
US10640508B2 (en) 2017-10-13 2020-05-05 Massachusetts Institute Of Technology Diazene directed modular synthesis of compounds with quaternary carbon centers
CR20250325A (es) * 2018-04-13 2025-08-29 Genentech Inc Formulaciones inmunoconjugadas anti-cd79b estables (divisional expediente 2020-0550)
GB201807870D0 (en) * 2018-05-15 2018-06-27 Autolus Ltd A CD79-specific chimeric antigen receptor
CN113194966A (zh) * 2018-10-03 2021-07-30 柰裴斯生命科学公司 抗cd79抗体及其应用
CN111116753A (zh) * 2018-10-30 2020-05-08 上海泰因生物技术有限公司 一种双特异性抗体的制备方法
CN111116745B (zh) 2018-11-01 2022-10-14 上海新理念生物医药科技有限公司 抗CD79b抗体、其药物偶联物及其应用
CA3118966A1 (fr) 2018-11-15 2020-05-22 Byondis B.V. Anticorps anti-sirpa humanises
KR20210100668A (ko) 2018-12-06 2021-08-17 제넨테크, 인크. 항-CD79b 면역접합체, 알킬화제 및 항-CD20 항체를 포함하는 미만성 큰 B-세포 림프종의 조합 요법
CN109493915B (zh) * 2018-12-12 2021-05-07 桂林电子科技大学 一种基于不确定图模型侦测蛋白质复合物的方法
US12600760B2 (en) 2018-12-13 2026-04-14 The General Hospital Corporation Chimeric antigen receptors targeting CD79B and CD19
TWI861039B (zh) 2018-12-21 2024-11-11 瑞士商赫孚孟拉羅股份公司 靶向腫瘤之促效cd28抗原結合分子
BR112021014420A2 (pt) 2019-01-28 2021-09-21 Tuojie Biotech (Shanghai) Co., Ltd. Anticorpo anti-cd79b, fragmento de ligação ao antígeno do mesmo e uso farmacêutico do mesmo
TW202100556A (zh) 2019-03-14 2021-01-01 美商建南德克公司 使用her2 t細胞依賴性雙特異性抗體之治療
CN111825742B (zh) * 2019-04-18 2024-01-30 陈铭 Ctpa作为特种偶合剂用于氨基酸离子液体的多肽固相合成
KR20220007136A (ko) 2019-05-14 2022-01-18 제넨테크, 인크. 소포 림프종을 치료하기 위한 항-CD79b 면역접합체의 사용 방법
US11535634B2 (en) 2019-06-05 2022-12-27 Massachusetts Institute Of Technology Compounds, conjugates, and compositions of epipolythiodiketopiperazines and polythiodiketopiperazines and uses thereof
CA3157509A1 (fr) 2019-10-10 2021-04-15 Kodiak Sciences Inc. Procedes de traitement d'un trouble oculaire
CN114945386A (zh) 2019-10-18 2022-08-26 基因泰克公司 使用抗CD79b免疫缀合物治疗弥漫性大B细胞淋巴瘤的方法
US11086075B2 (en) * 2019-10-30 2021-08-10 Alliance Fiber Optic Products, Inc. Fiber array units with mode-field diameter conversion, and fabrication method
CN111560383A (zh) * 2020-03-14 2020-08-21 天津大学青岛海洋技术研究院 促进枯草芽孢杆菌合成甲萘醌-7的重组菌及其基因修饰方法
CN115916822A (zh) 2020-04-24 2023-04-04 基因泰克公司 使用抗CD79b免疫缀合物的方法
CN116234572A (zh) * 2020-04-30 2023-06-06 安驰肿瘤公司 治疗性SIRPα抗体
US11834512B2 (en) 2020-05-04 2023-12-05 The Regents Of The University Of California Inhibiting anti-ENPP1 antibodies
CN111961136B (zh) * 2020-07-13 2022-07-08 厦门医学院 一种全人源化中和破伤风毒素的三价特异性抗体及其制备方法
CN111592598B (zh) * 2020-07-16 2021-08-10 西安迪赛生物药业有限责任公司 高三尖杉酯碱靶向治疗剂及其应用
CA3187245A1 (fr) 2020-08-17 2022-02-24 Sebastien Mercx Immunotoxine recombinante comprenant une ribotoxine ou une rnase
CN114249832B (zh) * 2020-09-24 2023-11-10 博源润生医药（杭州）有限公司 一种靶向cpsg4的人源化嵌合抗原受体及表达该嵌合抗原受体的免疫效应细胞及其应用
JP2023545099A (ja) 2020-10-08 2023-10-26 アフィメド ゲーエムベーハー 三重特異性バインダー
CA3196218A1 (fr) 2020-10-25 2022-04-28 Philipp SPYCHER Moyens et procedes de fabrication de conjugues anticorps-lieur
KR20230100732A (ko) 2020-11-04 2023-07-05 제넨테크, 인크. 항-cd20/항-cd3 이중특이성 항체의 피하 투여
AU2021374594B2 (en) 2020-11-04 2026-03-05 Genentech, Inc. Dosing for treatment with anti-cd20/anti-cd3 bispecific antibodies and anti-cd79b antibody drug conjugates
CA3196539A1 (fr) 2020-11-04 2022-05-12 Chi-Chung Li Dosage pour le traitement avec des anticorps bispecifiques anti-cd20/anti-cd3
US12564642B2 (en) 2020-11-10 2026-03-03 Sanofi CEACAM5 antibody-drug conjugate formulation
WO2022182415A1 (fr) 2021-02-24 2022-09-01 Massachusetts Institute Of Technology Dérivés d'himastatine, leurs procédés de préparation et leurs utilisations
CA3213632A1 (fr) 2021-04-30 2022-11-03 F. Hoffmann-La Roche Ag Dosage pour un traitement combine avec un anticorps bispecifique anti-cd20/anti-cd3 et un conjugue anticorps-medicament anti-cd79b
KR20240007184A (ko) 2021-05-12 2024-01-16 제넨테크, 인크. 미만성 거대 b세포 림프종을 치료하기 위해 항-cd79b 면역접합체를 사용하는 방법
US12291575B2 (en) 2021-05-14 2025-05-06 Genentech, Inc. Methods for treatment of CD20-positive proliferative disorder with mosunetuzumab and polatuzumab vedotin
CN113185572B (zh) * 2021-05-24 2023-03-17 江南大学 一种虎奶菇细胞壁糖蛋白的提取方法
CA3216098A1 (fr) 2021-07-30 2023-02-02 Uwe Reusch Corps duplex
US20240336697A1 (en) 2021-08-07 2024-10-10 Genentech, Inc. Methods of using anti-cd79b immunoconjugates to treat diffuse large b-cell lymphoma
CN114137203A (zh) * 2021-10-21 2022-03-04 广州万孚生物技术股份有限公司 抗原与碱性磷酸酶结合物的制备方法
AU2022382368A1 (en) 2021-11-03 2024-05-02 Affimed Gmbh Bispecific cd16a binders
EP4460331A1 (fr) * 2022-01-06 2024-11-13 PTM Therapeutics, Inc. Méthodes de traitement de tumeurs solides et compositions associées
IL314969A (en) 2022-02-17 2024-10-01 Atb Therapeutics Recombinant immunotoxin comprising a ribosome inactivating protein
WO2023180353A1 (fr) 2022-03-23 2023-09-28 F. Hoffmann-La Roche Ag Traitement combiné associant un anticorps bispécifique anti-cd20/anti-cd3 et une chimiothérapie
EP4534106A1 (fr) * 2022-06-03 2025-04-09 UBE Corporation Précurseur de conjugué anticorps-multimédicaments et intermédiaire synthétique de celui-ci
AU2023279443A1 (en) * 2022-06-03 2025-01-23 Ube Corporation Antibody-multidrug conjugate
CN115349490B (zh) * 2022-07-14 2024-01-12 成都中医药大学 一种卵巢储备功能低下动物模型的建立方法
EP4568997A1 (fr) 2022-08-08 2025-06-18 ATB Therapeutics Anticorps humanisés dirigés contre cd79b
CN115651881B (zh) * 2022-12-27 2023-03-28 广州傲农生物科技有限公司 一种益生菌复合菌液、制备方法及其应用
CN121285742A (zh) 2023-06-08 2026-01-06 基因泰克公司 用于淋巴瘤的诊断和治疗方法的巨噬细胞特征
CN116535509B (zh) * 2023-06-28 2023-11-03 上海偌妥生物科技有限公司 抗CD79b抗体、其制备方法及其应用
WO2025085781A1 (fr) 2023-10-19 2025-04-24 Genentech, Inc. Combinaisons de protéines de fusion fc hétérodimères il15/il15r alpha et d'anticorps bispécifiques her2xcd3 pour traiter des cancers her2-positifs
CN117783524B (zh) * 2024-02-26 2024-05-03 中国医学科学院医学生物学研究所 一种双抗体夹心法间接定量检测柯萨奇a10型病毒抗原的建立与应用
CN118542230B (zh) * 2024-05-24 2025-01-28 内蒙古农业大学 一种基于培养皿的农杆菌侵染苜蓿根系体系及其建立方法
US20260078198A1 (en) 2024-08-28 2026-03-19 Genentech, Inc. Methods for treating cancer using subcutaneous dosing of mosunetuzumab in combination with polatuzumab vedotin
WO2026052513A1 (fr) 2024-09-09 2026-03-12 Adcytherix Sas Conjugués anticorps-médicament comprenant un anticorps de liaison flt3
CN119859189B (zh) * 2025-03-21 2025-05-23 四川省肿瘤医院 一种抗cd79b蛋白单克隆抗体及其相关产品和用途

Family Cites Families (360)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US633410A (en) 1898-09-22 1899-09-19 George A Ames Ice-cutter.
US3445518A (en) 1966-05-06 1969-05-20 Warner Lambert Pharmaceutical P-acylphenylethylamines
US3720760A (en) 1968-09-06 1973-03-13 Pharmacia Ab Method for determining the presence of reagin-immunoglobulins(reagin-ig)directed against certain allergens,in aqueous samples
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US3896111A (en) 1973-02-20 1975-07-22 Research Corp Ansa macrolides
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4151042A (en) 1977-03-31 1979-04-24 Takeda Chemical Industries, Ltd. Method for producing maytansinol and its derivatives
US4137230A (en) 1977-11-14 1979-01-30 Takeda Chemical Industries, Ltd. Method for the production of maytansinoids
USRE30985E (en) 1978-01-01 1982-06-29 Serum-free cell culture media
FR2413974A1 (fr) 1978-01-06 1979-08-03 David Bernard Sechoir pour feuilles imprimees par serigraphie
US4265814A (en) 1978-03-24 1981-05-05 Takeda Chemical Industries Matansinol 3-n-hexadecanoate
US4307016A (en) 1978-03-24 1981-12-22 Takeda Chemical Industries, Ltd. Demethyl maytansinoids
US4275149A (en) 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
US4318980A (en) 1978-04-10 1982-03-09 Miles Laboratories, Inc. Heterogenous specific binding assay employing a cycling reactant as label
JPS5562090A (en) 1978-10-27 1980-05-10 Takeda Chem Ind Ltd Novel maytansinoid compound and its preparation
US4256746A (en) 1978-11-14 1981-03-17 Takeda Chemical Industries Dechloromaytansinoids, their pharmaceutical compositions and method of use
JPS5566585A (en) 1978-11-14 1980-05-20 Takeda Chem Ind Ltd Novel maytansinoid compound and its preparation
JPS55164687A (en) 1979-06-11 1980-12-22 Takeda Chem Ind Ltd Novel maytansinoid compound and its preparation
JPS55102583A (en) 1979-01-31 1980-08-05 Takeda Chem Ind Ltd 20-acyloxy-20-demethylmaytansinoid compound
JPS55162791A (en) 1979-06-05 1980-12-18 Takeda Chem Ind Ltd Antibiotic c-15003pnd and its preparation
JPS55164685A (en) 1979-06-08 1980-12-22 Takeda Chem Ind Ltd Novel maytansinoid compound and its preparation
JPS55164686A (en) 1979-06-11 1980-12-22 Takeda Chem Ind Ltd Novel maytansinoid compound and its preparation
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
US4309428A (en) 1979-07-30 1982-01-05 Takeda Chemical Industries, Ltd. Maytansinoids
JPS5645483A (en) 1979-09-19 1981-04-25 Takeda Chem Ind Ltd C-15003phm and its preparation
EP0028683A1 (fr) 1979-09-21 1981-05-20 Takeda Chemical Industries, Ltd. Antibiotique C-15003 PHO et sa préparation
JPS5645485A (en) 1979-09-21 1981-04-25 Takeda Chem Ind Ltd Production of c-15003pnd
WO1981001145A1 (fr) 1979-10-18 1981-04-30 Univ Illinois Medicaments "pro-drugs" pouvant etre actives par des enzymes hydrolytiques
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
ZA811368B (en) 1980-03-24 1982-04-28 Genentech Inc Bacterial polypedtide expression employing tryptophan promoter-operator
WO1982001188A1 (fr) 1980-10-08 1982-04-15 Takeda Chemical Industries Ltd Composes 4,5-deoxymaytansinoide et leur procede de preparation
US4450254A (en) 1980-11-03 1984-05-22 Standard Oil Company Impact improvement of high nitrile resins
US4419446A (en) 1980-12-31 1983-12-06 The United States Of America As Represented By The Department Of Health And Human Services Recombinant DNA process utilizing a papilloma virus DNA as a vector
US4313946A (en) 1981-01-27 1982-02-02 The United States Of America As Represented By The Secretary Of Agriculture Chemotherapeutically active maytansinoids from Trewia nudiflora
US4315929A (en) 1981-01-27 1982-02-16 The United States Of America As Represented By The Secretary Of Agriculture Method of controlling the European corn borer with trewiasine
JPS57192389A (en) 1981-05-20 1982-11-26 Takeda Chem Ind Ltd Novel maytansinoid
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
US4414205A (en) 1981-08-28 1983-11-08 University Patents, Inc. Cell growth inhibitory substances
NZ201705A (en) 1981-08-31 1986-03-14 Genentech Inc Recombinant dna method for production of hepatitis b surface antigen in yeast
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4943529A (en) 1982-05-19 1990-07-24 Gist-Brocades Nv Kluyveromyces as a host strain
US4601978A (en) 1982-11-24 1986-07-22 The Regents Of The University Of California Mammalian metallothionein promoter system
US4560655A (en) 1982-12-16 1985-12-24 Immunex Corporation Serum-free cell culture medium and process for making same
US4657866A (en) 1982-12-21 1987-04-14 Sudhir Kumar Serum-free, synthetic, completely chemically defined tissue culture media
US4713339A (en) 1983-01-19 1987-12-15 Genentech, Inc. Polycistronic expression vector construction
AU2353384A (en) 1983-01-19 1984-07-26 Genentech Inc. Amplification in eukaryotic host cells
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
DD266710A3 (de) 1983-06-06 1989-04-12 Ve Forschungszentrum Biotechnologie Verfahren zur biotechnischen Herstellung van alkalischer Phosphatase
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
AU3145184A (en) 1983-08-16 1985-02-21 Zymogenetics Inc. High expression of foreign genes in schizosaccharomyces pombe
US4767704A (en) 1983-10-07 1988-08-30 Columbia University In The City Of New York Protein-free culture medium
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
ATE97498T1 (de) 1984-01-30 1993-12-15 Imp Cancer Res Tech Verbesserungen an wachstumsfaktoren.
US5169774A (en) 1984-02-08 1992-12-08 Cetus Oncology Corporation Monoclonal anti-human breast cancer antibodies
US6054561A (en) 1984-02-08 2000-04-25 Chiron Corporation Antigen-binding sites of antibody molecules specific for cancer antigens
US4753894A (en) 1984-02-08 1988-06-28 Cetus Corporation Monoclonal anti-human breast cancer antibodies
US4965199A (en) 1984-04-20 1990-10-23 Genentech, Inc. Preparation of functional human factor VIII in mammalian cells using methotrexate based selection
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
US4764368A (en) 1984-08-29 1988-08-16 Dana-Farber Cancer Institute, Inc. Acid-cleavable compound
US5342606A (en) 1984-10-18 1994-08-30 Board Of Regents, The University Of Texas System Polyazamacrocyclic compounds for complexation of metal ions
US5316757A (en) 1984-10-18 1994-05-31 Board Of Regents, The University Of Texas System Synthesis of polyazamacrocycles with more than one type of side-chain chelating groups
US4879231A (en) 1984-10-30 1989-11-07 Phillips Petroleum Company Transformation of yeasts of the genus pichia
US4737456A (en) 1985-05-09 1988-04-12 Syntex (U.S.A.) Inc. Reducing interference in ligand-receptor binding assays
DE3675588D1 (de) 1985-06-19 1990-12-20 Ajinomoto Kk Haemoglobin, das an ein poly(alkenylenoxid) gebunden ist.
GB8516415D0 (en) 1985-06-28 1985-07-31 Celltech Ltd Culture of animal cells
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US5583024A (en) 1985-12-02 1996-12-10 The Regents Of The University Of California Recombinant expression of Coleoptera luciferase
US5091178A (en) 1986-02-21 1992-02-25 Oncogen Tumor therapy with biologically active anti-tumor antibodies
AU597574B2 (en) 1986-03-07 1990-06-07 Massachusetts Institute Of Technology Method for enhancing glycoprotein stability
US4927762A (en) 1986-04-01 1990-05-22 Cell Enterprises, Inc. Cell culture medium with antioxidant
GB8610600D0 (en) 1986-04-30 1986-06-04 Novo Industri As Transformation of trichoderma
US5401638A (en) 1986-06-04 1995-03-28 Oncogene Science, Inc. Detection and quantification of neu related proteins in the biological fluids of humans
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
US5567610A (en) 1986-09-04 1996-10-22 Bioinvent International Ab Method of producing human monoclonal antibodies and kit therefor
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
US4946783A (en) 1987-01-30 1990-08-07 President And Fellows Of Harvard College Periplasmic protease mutants of Escherichia coli
GB8705477D0 (en) 1987-03-09 1987-04-15 Carlton Med Prod Drug delivery systems
US4816444A (en) 1987-07-10 1989-03-28 Arizona Board Of Regents, Arizona State University Cell growth inhibitory substance
US5010182A (en) 1987-07-28 1991-04-23 Chiron Corporation DNA constructs containing a Kluyveromyces alpha factor leader sequence for directing secretion of heterologous polypeptides
US4975278A (en) 1988-02-26 1990-12-04 Bristol-Myers Company Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells
GB8724885D0 (en) 1987-10-23 1987-11-25 Binns M M Fowlpox virus promotors
US5053394A (en) 1988-09-21 1991-10-01 American Cyanamid Company Targeted forms of methyltrithio antitumor agents
US5606040A (en) 1987-10-30 1997-02-25 American Cyanamid Company Antitumor and antibacterial substituted disulfide derivatives prepared from compounds possessing a methyl-trithio group
US5770701A (en) 1987-10-30 1998-06-23 American Cyanamid Company Process for preparing targeted forms of methyltrithio antitumor agents
US5283187A (en) 1987-11-17 1994-02-01 Brown University Research Foundation Cell culture-containing tubular capsule produced by co-extrusion
US4892538A (en) 1987-11-17 1990-01-09 Brown University Research Foundation In vivo delivery of neurotransmitters by implanted, encapsulated cells
ATE105585T1 (de) 1987-12-21 1994-05-15 Univ Toledo Transformation von keimenden pflanzensamen mit hilfe von agrobacterium.
WO1989006692A1 (fr) 1988-01-12 1989-07-27 Genentech, Inc. Procede de traitement de cellules tumorales par inhibition de la fonction receptrice du facteur de croissance
IL106992A (en) 1988-02-11 1994-06-24 Bristol Myers Squibb Co Acylhydrazone derivatives of anthracycline and methods for their preparation
US4943628A (en) 1988-06-13 1990-07-24 Ortho Pharmaceutical Corporation HIV peptide-inducted T cell stimulation
AU4005289A (en) 1988-08-25 1990-03-01 Smithkline Beecham Corporation Recombinant saccharomyces
AU632065B2 (en) 1988-09-23 1992-12-17 Novartis Vaccines And Diagnostics, Inc. Cell culture medium for enhanced cell growth, culture longevity and product expression
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5175384A (en) 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US4978744A (en) 1989-01-27 1990-12-18 Arizona Board Of Regents Synthesis of dolastatin 10
US5225538A (en) 1989-02-23 1993-07-06 Genentech, Inc. Lymphocyte homing receptor/immunoglobulin fusion proteins
ATE144281T1 (de) 1989-04-28 1996-11-15 Rhein Biotech Proz & Prod Gmbh Hefezellen der gattung-schwanniomyces
FR2646437B1 (fr) 1989-04-28 1991-08-30 Transgene Sa Nouvelles sequences d'adn, leur application en tant que sequence codant pour un peptide signal pour la secretion de proteines matures par des levures recombinantes, cassettes d'expression, levures transformees et procede de preparation de proteines correspondant
US4879278A (en) 1989-05-16 1989-11-07 Arizona Board Of Regents Isolation and structural elucidation of the cytostatic linear depsipeptide dolastatin 15
EP0402226A1 (fr) 1989-06-06 1990-12-12 Institut National De La Recherche Agronomique Vecteurs de transformation de la levure yarrowia
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
ES2096590T3 (es) 1989-06-29 1997-03-16 Medarex Inc Reactivos biespecificos para la terapia del sida.
FR2649120B1 (fr) 1989-06-30 1994-01-28 Cayla Nouvelle souche et ses mutants de champignons filamenteux, procede de production de proteines recombinantes a l'aide de ladite souche et souches et proteines obtenues selon ce procede
US5286637A (en) 1989-08-07 1994-02-15 Debiopharm, S.A. Biologically active drug polymer derivatives and method for preparing same
DE68926248T2 (de) 1989-09-29 1996-12-19 Oncogene Science Inc p100 "neu" menschlisches Protein and Verwendung dieses Proteins zum Nachweis von preneoplasmatischen- oder neoplasmatischen beim Menschen
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
CA2026147C (fr) 1989-10-25 2006-02-07 Ravi J. Chari Agents cytotoxiques comprenant des maytansinoides et leur usage therapeutique
US5208020A (en) * 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
US5165923A (en) 1989-11-20 1992-11-24 Imperial Cancer Research Technology Methods and compositions for the treatment of hodgkin's disease
US6150584A (en) * 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5229275A (en) 1990-04-26 1993-07-20 Akzo N.V. In-vitro method for producing antigen-specific human monoclonal antibodies
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
US5767236A (en) 1990-05-09 1998-06-16 Biomeasure, Inc. Linear therapeutic peptides
US5179774A (en) 1990-05-24 1993-01-19 Ford Motor Company Apparatus and method for mechanically applying a sealing strip
US5723286A (en) 1990-06-20 1998-03-03 Affymax Technologies N.V. Peptide library and screening systems
DE69132709T2 (de) 1990-06-29 2002-06-20 Large Scale Biology Corp., Vacaville Melaninproduktion durch transformierte mikroorganismen
US6172197B1 (en) 1991-07-10 2001-01-09 Medical Research Council Methods for producing members of specific binding pairs
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
ATE300615T1 (de) 1990-08-29 2005-08-15 Genpharm Int Transgene mäuse fähig zur produktion heterologer antikörper
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5122469A (en) 1990-10-03 1992-06-16 Genentech, Inc. Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
US5508192A (en) 1990-11-09 1996-04-16 Board Of Regents, The University Of Texas System Bacterial host strains for producing proteolytically sensitive polypeptides
US5264365A (en) 1990-11-09 1993-11-23 Board Of Regents, The University Of Texas System Protease-deficient bacterial strains for production of proteolytically sensitive polypeptides
CA2405246A1 (fr) 1990-12-03 1992-06-11 Genentech, Inc. Methode d'enrichissement de proteines variantes aux proprietes liantes a lterees
US5206161A (en) 1991-02-01 1993-04-27 Genentech, Inc. Human plasma carboxypeptidase B
US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
DK0580737T3 (da) 1991-04-10 2004-11-01 Scripps Research Inst Heterodimere receptorbiblioteker ved anvendelse af phagemider
EP0586505A1 (fr) 1991-05-14 1994-03-16 Repligen Corporation Anticorps d'heteroconjugues pour le traitement des infections a l'hiv
EP1400536A1 (fr) 1991-06-14 2004-03-24 Genentech Inc. Procédé pour fabriquer des anticorps humanisés
WO1994004679A1 (fr) 1991-06-14 1994-03-03 Genentech, Inc. Procede pour fabriquer des anticorps humanises
JP3050424B2 (ja) 1991-07-12 2000-06-12 塩野義製薬株式会社 ヒトエンドセリンリセプター
DE69232552T2 (de) 1991-08-09 2002-10-31 Teikoku Hormone Mfg. Co., Ltd. Tetrapeptide Derivat
AU669124B2 (en) * 1991-09-18 1996-05-30 Kyowa Hakko Kirin Co., Ltd. Process for producing humanized chimera antibody
WO1993006217A1 (fr) 1991-09-19 1993-04-01 Genentech, Inc. EXPRESSION DANS L'E. COLI DE FRAGMENTS D'ANTICORPS POSSEDANT AU MOINS UNE CYSTEINE PRESENTE SOUS FORME D'UN THIOL LIBRE, ET LEUR UTILISATION DANS LA PRODUCTION D'ANTICORPS BIFONCTIONNELS F(ab')¿2?
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
US5362852A (en) 1991-09-27 1994-11-08 Pfizer Inc. Modified peptide derivatives conjugated at 2-hydroxyethylamine moieties
FI941572L (fi) 1991-10-07 1994-05-27 Oncologix Inc Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenetelmä
US5270170A (en) 1991-10-16 1993-12-14 Affymax Technologies N.V. Peptide library and screening method
WO1993008829A1 (fr) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions induisant la destruction de cellules infectees par l'hiv
DE69232137T2 (de) 1991-11-25 2002-05-29 Enzon Inc Multivalente antigen-bindende proteine
US5428139A (en) 1991-12-10 1995-06-27 The Dow Chemical Company Bicyclopolyazamacrocyclophosphonic acid complexes for use as radiopharmaceuticals
US5739294A (en) 1991-12-10 1998-04-14 The Dow Chemical Company Bicyclopol yazamacrocyclophosphonic acid complexes for use as contrast agents
US5480990A (en) 1991-12-10 1996-01-02 The Dow Chemical Company Bicyclopolyazamacrocyclocarboxylic acid complexes for use as contrast agents
US5622929A (en) 1992-01-23 1997-04-22 Bristol-Myers Squibb Company Thioether conjugates
US5667988A (en) 1992-01-27 1997-09-16 The Scripps Research Institute Methods for producing antibody libraries using universal or randomized immunoglobulin light chains
AU675929B2 (en) 1992-02-06 1997-02-27 Curis, Inc. Biosynthetic binding protein for cancer marker
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
US5573905A (en) 1992-03-30 1996-11-12 The Scripps Research Institute Encoded combinatorial chemical libraries
ZA932522B (en) 1992-04-10 1993-12-20 Res Dev Foundation Immunotoxins directed against c-erbB-2(HER/neu) related surface antigens
EP0646178A1 (fr) 1992-06-04 1995-04-05 The Regents Of The University Of California Cassette d'expression avec des regious regulatrices fonctionnelles chez le mammifere hote
EP0656064B1 (fr) 1992-08-17 1997-03-05 Genentech, Inc. Immunoadhesines bispecifiques
MD1367C2 (ro) 1992-11-13 2000-11-30 Idec Pharmaceuticals Corporation Metode de tratament al limfomului celulelor B, anticorpi anti-CD20, hibridom.
US5635483A (en) 1992-12-03 1997-06-03 Arizona Board Of Regents Acting On Behalf Of Arizona State University Tumor inhibiting tetrapeptide bearing modified phenethyl amides
US6569834B1 (en) 1992-12-03 2003-05-27 George R. Pettit Elucidation and synthesis of antineoplastic tetrapeptide w-aminoalkyl-amides
US6034065A (en) 1992-12-03 2000-03-07 Arizona Board Of Regents Elucidation and synthesis of antineoplastic tetrapeptide phenethylamides of dolastatin 10
CA2109861C (fr) 1992-12-04 1999-03-16 Shu-Hui Chen Paclitaxels modifies en 6,7
ATE199392T1 (de) 1992-12-04 2001-03-15 Medical Res Council Multivalente und multispezifische bindungsproteine, deren herstellung und verwendung
US5644033A (en) * 1992-12-22 1997-07-01 Health Research, Inc. Monoclonal antibodies that define a unique antigen of human B cell antigen receptor complex and methods of using same for diagnosis and treatment
US5410024A (en) 1993-01-21 1995-04-25 Arizona Board Of Regents Acting On Behalf Of Arizona State University Human cancer inhibitory pentapeptide amides
US5780588A (en) 1993-01-26 1998-07-14 Arizona Board Of Regents Elucidation and synthesis of selected pentapeptides
JPH06234790A (ja) 1993-02-09 1994-08-23 Teikoku Hormone Mfg Co Ltd 新規テトラペプチドアミド誘導体
US5869445A (en) 1993-03-17 1999-02-09 University Of Washington Methods for eliciting or enhancing reactivity to HER-2/neu protein
PT616812E (pt) 1993-03-24 2000-04-28 Berlex Biosciences Combinacao de compostos anti-hormonais e moleculas de ligacao no tratamento do cancro
US5385893A (en) 1993-05-06 1995-01-31 The Dow Chemical Company Tricyclopolyazamacrocyclophosphonic acids, complexes and derivatives thereof, for use as contrast agents
US5462725A (en) 1993-05-06 1995-10-31 The Dow Chemical Company 2-pyridylmethylenepolyazamacrocyclophosphonic acids, complexes and derivatives thereof, for use as contrast agents
US6214345B1 (en) 1993-05-14 2001-04-10 Bristol-Myers Squibb Co. Lysosomal enzyme-cleavable antitumor drug conjugates
JPH0719832A (ja) * 1993-06-21 1995-01-20 Canon Inc 複数画像の対応点抽出方法
KR100332254B1 (ko) 1993-10-01 2002-09-27 데이꼬꾸 조끼 세이야꾸 가부시키가이샤 신규인펩티드유도체
US5553097A (en) 1994-06-01 1996-09-03 International Business Machines Corporation System and method for transporting high-bandwidth signals over electrically conducting transmission lines
US5773001A (en) 1994-06-03 1998-06-30 American Cyanamid Company Conjugates of methyltrithio antitumor agents and intermediates for their synthesis
US5504191A (en) 1994-08-01 1996-04-02 Arizona Board Of Regents Acting On Behalf Of Arizona State University Human cancer inhibitory pentapeptide methyl esters
US5530097A (en) 1994-08-01 1996-06-25 Arizona Board Of Regents Acting On Behalf Of Arizona State University Human cancer inhibitory peptide amides
US5521284A (en) 1994-08-01 1996-05-28 Arizona Board Of Regents Acting On Behalf Of Arizona State University Human cancer inhibitory pentapeptide amides and esters
US5910486A (en) 1994-09-06 1999-06-08 Uab Research Foundation Methods for modulating protein function in cells using, intracellular antibody homologues
US5554725A (en) 1994-09-14 1996-09-10 Arizona Board Of Regents Acting On Behalf Of Arizona State University Synthesis of dolastatin 15
US5789199A (en) 1994-11-03 1998-08-04 Genentech, Inc. Process for bacterial production of polypeptides
US5639635A (en) 1994-11-03 1997-06-17 Genentech, Inc. Process for bacterial production of polypeptides
US6214388B1 (en) 1994-11-09 2001-04-10 The Regents Of The University Of California Immunoliposomes that optimize internalization into target cells
US5599902A (en) 1994-11-10 1997-02-04 Arizona Board Of Regents Acting On Behalf Of Arizona State University Cancer inhibitory peptides
JPH10511085A (ja) 1994-12-02 1998-10-27 カイロン コーポレイション 二重特異性抗体を用いる免疫応答を促進する方法
US5663149A (en) 1994-12-13 1997-09-02 Arizona Board Of Regents Acting On Behalf Of Arizona State University Human cancer inhibitory pentapeptide heterocyclic and halophenyl amides
WO1996022384A1 (fr) 1995-01-18 1996-07-25 Boehringer Mannheim Gmbh Anticorps anti-cd30 prevenant le clivage proteolytique et la liberation de l'antigene cd30 membranaire
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5840523A (en) 1995-03-01 1998-11-24 Genetech, Inc. Methods and compositions for secretion of heterologous polypeptides
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
JPH08336393A (ja) 1995-04-13 1996-12-24 Mitsubishi Chem Corp 光学活性なγ−置換−β−ヒドロキシ酪酸エステルの製造法
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US5739277A (en) 1995-04-14 1998-04-14 Genentech Inc. Altered polypeptides with increased half-life
WO1996033212A1 (fr) 1995-04-21 1996-10-24 Teikoku Hormone Mfg. Co., Ltd. Nouveaux derives peptidiques
US5837234A (en) 1995-06-07 1998-11-17 Cytotherapeutics, Inc. Bioartificial organ containing cells encapsulated in a permselective polyether suflfone membrane
US5712374A (en) 1995-06-07 1998-01-27 American Cyanamid Company Method for the preparation of substantiallly monomeric calicheamicin derivative/carrier conjugates
US5714586A (en) 1995-06-07 1998-02-03 American Cyanamid Company Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates
FR2737588B1 (fr) 1995-08-01 2001-11-02 Kodak Pathe Nouveau produit pour radiographie industrielle
JPH0977791A (ja) 1995-09-08 1997-03-25 Nippon Kayaku Co Ltd ペプチド誘導体及びその用途
SE9503380D0 (sv) 1995-09-29 1995-09-29 Pharmacia Ab Protein derivatives
DE19544393A1 (de) 1995-11-15 1997-05-22 Hoechst Schering Agrevo Gmbh Synergistische herbizide Mischungen
US5783186A (en) 1995-12-05 1998-07-21 Amgen Inc. Antibody-induced apoptosis
DE69726404T2 (de) 1996-01-05 2004-09-09 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Mesothelinantigen, verfahren und testsatz zur targetierung
US5834456A (en) 1996-02-23 1998-11-10 The Dow Chemical Company Polyazamacrocyclofluoromonoalkylphosphonic acids, and their complexes, for use as contrast agents
WO1997038123A1 (fr) 1996-04-05 1997-10-16 Board Of Regents, The University Of Texas System Procedes de production de proteines eucaryotes, solubles, actives sur plan biologique et contenant des liaisons disulfure, a l'interieur de cellules bacteriennes
US5922845A (en) 1996-07-11 1999-07-13 Medarex, Inc. Therapeutic multispecific compounds comprised of anti-Fcα receptor antibodies
US5741892A (en) 1996-07-30 1998-04-21 Basf Aktiengesellschaft Pentapeptides as antitumor agents
DE69832158T2 (de) 1997-02-25 2006-08-10 Arizona Board Of Regents, Tempe Isolierung und strukturelle aufklärung der kryostatischen linearen und cyclo-depsipeptide dolastatin 16, dolastatin 17, und dolastatin 18
US5965537A (en) 1997-03-10 1999-10-12 Basf Aktiengesellschaft Dolastatin 15 derivatives with carbonyl and heterocyclic functionalities at the C-terminus
US6183744B1 (en) 1997-03-24 2001-02-06 Immunomedics, Inc. Immunotherapy of B-cell malignancies using anti-CD22 antibodies
US5994071A (en) 1997-04-04 1999-11-30 Albany Medical College Assessment of prostate cancer
US6319688B1 (en) 1997-04-28 2001-11-20 Smithkline Beecham Corporation Polynucleotide encoding human sodium dependent phosphate transporter (IPT-1)
US6184105B1 (en) 1997-05-22 2001-02-06 Advanced Micro Devices Method for post transistor isolation
US6083715A (en) 1997-06-09 2000-07-04 Board Of Regents, The University Of Texas System Methods for producing heterologous disulfide bond-containing polypeptides in bacterial cells
US6172213B1 (en) * 1997-07-02 2001-01-09 Genentech, Inc. Anti-IgE antibodies and method of improving polypeptides
US6143721A (en) 1997-07-18 2000-11-07 Basf Aktiengesellschaft Dolastatin 15 derivatives
US6248564B1 (en) * 1997-08-29 2001-06-19 Harvard University Mutant MHC class I molecules
US6602677B1 (en) 1997-09-19 2003-08-05 Promega Corporation Thermostable luciferases and methods of production
JP3992298B2 (ja) 1997-10-03 2007-10-17 中外製薬株式会社 天然ヒト型化抗体
WO1999035164A1 (fr) 1998-01-09 1999-07-15 Arizona Board Of Regents, A Body Corporate, Acting On Behalf Of Arizona State University Peptides anti-cryptococcus
US6051228A (en) 1998-02-19 2000-04-18 Bristol-Myers Squibb Co. Antibodies against human CD40
US6162930A (en) 1998-03-06 2000-12-19 Baylor University Anti-mitotic agents which inhibit tubulin polymerization
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
ES2292236T3 (es) 1998-04-02 2008-03-01 Genentech, Inc. Variantes de anticuerpos y sus fragmentos.
US6528624B1 (en) 1998-04-02 2003-03-04 Genentech, Inc. Polypeptide variants
AU757698C (en) 1998-06-01 2004-04-08 Agensys, Inc. Novel serpentine transmembrane antigens expressed in human cancers and uses thereof
US5985837A (en) 1998-07-08 1999-11-16 Basf Aktiengesellschaft Dolastatin 15 derivatives
WO2000012130A1 (fr) 1998-08-27 2000-03-09 Smithkline Beecham Corporation Agonistes et antagonistes de rp105
HU230769B1 (hu) 1999-01-15 2018-03-28 Genentech Inc. Módosított effektor-funkciójú polipeptid-változatok
US20040141983A1 (en) 1999-03-15 2004-07-22 Protein Design Labs, Inc. Compositions against cancer antigen LIV-1 and uses thereof
EP1179541B1 (fr) 1999-04-28 2004-06-16 Board Of Regents, The University Of Texas System Compositions et procédes de traitment du cancer par l'inhibition sélective du VEGF
CA2376596C (fr) 1999-06-25 2009-10-06 Genentech, Inc. Anticorps anti-erbb2 humanises et traitement a l'aide de ces anticorps
US6323315B1 (en) 1999-09-10 2001-11-27 Basf Aktiengesellschaft Dolastatin peptides
US7303749B1 (en) 1999-10-01 2007-12-04 Immunogen Inc. Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents
AU775373B2 (en) 1999-10-01 2004-07-29 Immunogen, Inc. Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents
US6346249B1 (en) * 1999-10-22 2002-02-12 Ludwig Institute For Cancer Research Methods for reducing the effects of cancers that express A33 antigen using A33 antigen specific immunoglobulin products
US6372907B1 (en) 1999-11-03 2002-04-16 Apptera Corporation Water-soluble rhodamine dye peptide conjugates
DK1244705T3 (da) 1999-12-06 2010-05-31 Agensys Inc Serpentintransmembrane antigener udtryk i human prostatacancere og anvendelser deraf
EP2180054A1 (fr) 1999-12-24 2010-04-28 Genentech, Inc. Procédés et compositions pour prolonger la demi-vie d'élimination de composés bioactifs
US20040001827A1 (en) 2002-06-28 2004-01-01 Dennis Mark S. Serum albumin binding peptides for tumor targeting
AU2001243142A1 (en) 2000-02-03 2001-08-14 Hyseq, Inc. Novel nucleic acids and polypeptides
US20040002068A1 (en) 2000-03-01 2004-01-01 Corixa Corporation Compositions and methods for the detection, diagnosis and therapy of hematological malignancies
NO20001182L (no) 2000-03-08 2001-09-10 Per Gunnar Werner Implanteringsmetode og apparat for hartransplantasjon
US7097840B2 (en) 2000-03-16 2006-08-29 Genentech, Inc. Methods of treatment using anti-ErbB antibody-maytansinoid conjugates
CN1423700A (zh) * 2000-03-24 2003-06-11 麦克美特股份公司 含有针对nkg2d受体复合物的表位的结合位点的多功能多肽
CN1981868A (zh) 2000-03-31 2007-06-20 拜奥根Idec公司 抗细胞因子抗体或拮抗剂与抗－cd20在b细胞淋巴瘤治疗中的联合应用
US6333410B1 (en) 2000-08-18 2001-12-25 Immunogen, Inc. Process for the preparation and purification of thiol-containing maytansinoids
US20020150573A1 (en) * 2000-11-10 2002-10-17 The Rockefeller University Anti-Igalpha-Igbeta antibody for lymphoma therapy
US20070258987A1 (en) 2000-11-28 2007-11-08 Seattle Genetics, Inc. Recombinant Anti-Cd30 Antibodies and Uses Thereof
US7090843B1 (en) 2000-11-28 2006-08-15 Seattle Genetics, Inc. Recombinant anti-CD30 antibodies and uses thereof
US20040018194A1 (en) 2000-11-28 2004-01-29 Francisco Joseph A. Recombinant anti-CD30 antibodies and uses thereof
RU2285541C2 (ru) 2000-12-22 2006-10-20 Байоджен Айдек Инк. Комбинированная терапия для лечения аутоиммунных заболеваний с использованием комбинации элиминирующего в-клетки/иммунорегуляторного антител
WO2002064842A2 (fr) 2001-02-13 2002-08-22 Children`S Hospital Research Foundation Analyse quantitative rapide par pcr du virus d'epstein-barr
MXPA03009510A (es) 2001-04-17 2005-04-29 Univ Arkansas Secuencias de repeticion del gen ca125 y su uso para intervenciones de diagnosticos y terapeuticas.
US20030083263A1 (en) 2001-04-30 2003-05-01 Svetlana Doronina Pentapeptide compounds and uses related thereto
US6884869B2 (en) 2001-04-30 2005-04-26 Seattle Genetics, Inc. Pentapeptide compounds and uses related thereto
US6441163B1 (en) 2001-05-31 2002-08-27 Immunogen, Inc. Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents
US20050107595A1 (en) 2001-06-20 2005-05-19 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
US7803915B2 (en) 2001-06-20 2010-09-28 Genentech, Inc. Antibody compositions for the diagnosis and treatment of tumor
MXPA05000511A (es) 2001-07-12 2005-09-30 Jefferson Foote Anticuepros super humanizados.
US6737409B2 (en) 2001-07-19 2004-05-18 Hoffmann-La Roche Inc. Dolastatin 10 derivatives
US20040235068A1 (en) 2001-09-05 2004-11-25 Levinson Arthur D. Methods for the identification of polypeptide antigens associated with disorders involving aberrant cell proliferation and compositions useful for the treatment of such disorders
US7098305B2 (en) 2001-09-06 2006-08-29 Ardana Bioscience Limited Sustained release of microcrystalline peptide suspensions
ES2537074T3 (es) 2001-09-06 2015-06-02 Agensys, Inc. Ácido nucleico y proteína correspondiente denominados STEAP-1 útiles en el tratamiento y la detección de cáncer
EP1487877B1 (fr) 2001-09-18 2010-10-27 Genentech, Inc. Compositions et procedes pour le diagnostic de tumeurs
WO2003026577A2 (fr) 2001-09-24 2003-04-03 Seattle Genetics, Inc. P-aminobenzyl ether dans des agents d'administration de medicaments
US7091186B2 (en) 2001-09-24 2006-08-15 Seattle Genetics, Inc. p-Amidobenzylethers in drug delivery agents
US20050123925A1 (en) 2002-11-15 2005-06-09 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
US20050238650A1 (en) 2002-04-17 2005-10-27 Genentech, Inc. Compositions and methods for the treatment of tumor of hematopoietic origin
US20110045005A1 (en) * 2001-10-19 2011-02-24 Craig Crowley Compositions and methods for the treatment of tumor of hematopoietic origin
WO2004016225A2 (fr) 2002-08-19 2004-02-26 Genentech, Inc. Compositions et methodes de diagnostic et de traitement des tumeurs
WO2003034903A2 (fr) 2001-10-23 2003-05-01 Psma Development Company, L.L.C. Anticorps et multimeres de proteines psma
CA2467242A1 (fr) 2001-11-20 2003-05-30 Seattle Genetics, Inc. Traitement des troubles immunologiques au moyen des anticorps anti-cd30
US20040001828A1 (en) 2002-02-21 2004-01-01 Joseph Tuscano Treatment methods using anti-CD22 antibodies
KR101017732B1 (ko) 2002-03-01 2011-02-28 이뮤노메딕스, 인코오포레이티드 내재화 항-ｃｄ74 항체 및 그 이용방법
KR101104655B1 (ko) 2002-03-08 2012-01-13 애보트 바이오테라퓨틱스 코포레이션 암 항원 ｔｍｅｆｆ２ 에 대한 항체 및 이의 용도
CA2479732A1 (fr) 2002-03-19 2003-10-02 Curagen Corporation Polypeptides therapeutiques, acides nucleiques codant pour ceux-ci et methodes d'utilisation associees
US20070207142A1 (en) * 2002-05-08 2007-09-06 Genentech, Inc. Compositions and methods for the treatment of tumor of hematopoietic origin
US20090068178A1 (en) 2002-05-08 2009-03-12 Genentech, Inc. Compositions and Methods for the Treatment of Tumor of Hematopoietic Origin
AU2003245441A1 (en) 2002-06-12 2003-12-31 Avalon Pharmaceuticals, Inc. Cancer-linked gene as target for chemotherapy
JP4364121B2 (ja) 2002-06-20 2009-11-11 スナップトラック・インコーポレーテッド 結合されたｇｐｓ受信器と通信システムにおける相互干渉の低減
WO2004001004A2 (fr) 2002-06-21 2003-12-31 Johns Hopkins University School Of Medicine Marqueurs de l'endothelium tumoral associe a une membrane
CA2491017A1 (fr) 2002-07-03 2004-01-15 Immunogen, Inc. Anticorps contre muc1 et muc16 non liberees et leurs utilisations
SI1545613T1 (sl) 2002-07-31 2011-11-30 Seattle Genetics Inc Avristatinski konjugati in njihova uporaba za zdravljenje raka avtoimunske bolezni ali infekcijskebolezni
AU2003294210A1 (en) 2002-07-31 2004-05-04 Seattle Genetics, Inc Anti-cd20 antibody-drug conjugates for the treatment of cancer and immune disorders
JP2006500364A (ja) 2002-08-16 2006-01-05 イムノージェン インコーポレーテッド 高い反応性と溶解度を有する架橋剤および小分子薬物の標的化送達用コンジュゲートの調製におけるそれらの使用
EP1391213A1 (fr) 2002-08-21 2004-02-25 Boehringer Ingelheim International GmbH Compositions et méthodes pour le traitement du cancer en utilisant un conjugué d'un anticorps contre le CD44 avec un maytansinoide et des agents chimiothérapeutiques
WO2004042017A2 (fr) 2002-10-31 2004-05-21 Genentech, Inc. Methodes et compositions pouvant augmenter la production d'anticorps
JP2006507322A (ja) 2002-11-14 2006-03-02 シンタルガ・ビーブイ 多重自己脱離放出スペーサーとして構築されたプロドラッグ
CA2508519A1 (fr) 2002-12-02 2004-06-17 The Government Of The United States Of America, As Represented By The Se Cretary Of The Department Of Health And Human Services Immunotoxine recombinante et son utilisation dans le traitement de tumeurs
CA2510315C (fr) 2002-12-20 2014-01-28 Abbvie Biotherapeutics Inc. Anticorps anti-gpr64 et utilisations
AU2003303543A1 (en) 2002-12-26 2004-07-29 Chugai Seiyaku Kabushiki Kaisha Agonist antibody against heteroreceptor
CA2513113A1 (fr) 2003-01-23 2004-08-05 Genentech, Inc. Procedes de production d'anticoprs humanises et d'amelioration du rendement d'anticorps ou de fragments de liaison d'antigenes en culture cellulaire
AU2004213053C1 (en) 2003-02-20 2009-07-16 Seagen Inc. Anti-CD70 antibody-drug conjugates and their use for the treatment of cancer and immune disorders
US20080025989A1 (en) 2003-02-20 2008-01-31 Seattle Genetics, Inc. Anti-cd70 antibody-drug conjugates and their use for the treatment of cancer and immune disorders
DK1613750T3 (en) 2003-03-19 2016-01-18 Amgen Fremont Inc ANTIBODIES TO T CELL AND MUCINDO immunoglobulin-binding domain 1 (TIM-1) antigen and uses thereof
US20110042260A1 (en) * 2003-04-10 2011-02-24 Craig Crowley Compositions and methods for the treatment of tumor of hematopoietic origin
US7755007B2 (en) 2003-04-17 2010-07-13 K&H Manufacturing, Inc Heated pet mat
US7432088B2 (en) 2003-05-08 2008-10-07 Immunogen Inc. Methods for the production of ansamitocins
US8088387B2 (en) * 2003-10-10 2012-01-03 Immunogen Inc. Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates
US7276497B2 (en) 2003-05-20 2007-10-02 Immunogen Inc. Cytotoxic agents comprising new maytansinoids
ES2672640T3 (es) 2003-11-05 2018-06-15 Roche Glycart Ag Moléculas de unión a antígeno con afinidad de unión a receptores Fc y función efectora incrementadas
US7498298B2 (en) 2003-11-06 2009-03-03 Seattle Genetics, Inc. Monomethylvaline compounds capable of conjugation to ligands
SI2295073T1 (sl) 2003-11-17 2014-07-31 Genentech, Inc. Protitelo proti CD22 za zdravljenje tumorja hematopoetskega izvora
US20060204496A1 (en) 2003-11-28 2006-09-14 Tetsuo Kojima Agonist antibody against heteroreceptor
EP1718667B1 (fr) 2004-02-23 2013-01-09 Genentech, Inc. Liants et conjugues heterocycliques auto-immolateurs
AU2005218642B2 (en) 2004-03-02 2011-04-28 Seagen Inc. Partially loaded antibodies and methods of their conjugation
US7399469B2 (en) 2004-03-26 2008-07-15 Pdl Biopharma, Inc. Anti-LFL2 antibodies for the diagnosis, prognosis and treatment of cancer
WO2005101017A1 (fr) 2004-04-07 2005-10-27 Genentech, Inc. Spectrometrie de masse de conjugues d'anticorps
KR20120064120A (ko) 2004-06-01 2012-06-18 제넨테크, 인크. 항체 약물 접합체 및 방법
CA2567914A1 (fr) 2004-06-02 2005-12-15 F. Hoffmann-La Roche Ag Synthese d'ester alkylique d'acide amino-alcoxy-heptanoique
JP2008503498A (ja) 2004-06-17 2008-02-07 マンカインド コーポレイション 癌の診断及び免疫療法における腫瘍関連抗原プロファイル
US7410772B2 (en) * 2004-07-02 2008-08-12 Genentech, Inc. Compositions and methods for treatment of non-Hodgkin's lymphoma
AU2005271892A1 (en) 2004-07-10 2006-02-16 Alexion Pharmaceuticals, Inc. Methods for discovering antibodies specific to cancer cells and antibodies discovered thereby
EP1773885B1 (fr) 2004-08-05 2010-04-21 Genentech, Inc. Antagonistes anti-cmet humanises
KR101270829B1 (ko) 2004-09-23 2013-06-07 제넨테크, 인크. 시스테인 유전자조작 항체 및 접합체
US20100111856A1 (en) 2004-09-23 2010-05-06 Herman Gill Zirconium-radiolabeled, cysteine engineered antibody conjugates
JP2008515889A (ja) 2004-10-05 2008-05-15 ジェネンテック・インコーポレーテッド 毒性の低下した治療剤
WO2006132670A2 (fr) 2004-11-12 2006-12-14 Seattle Genetics, Inc. Auristatines comportant une unite d'acide aminobenzoique au n-terminal
AU2005322410B2 (en) 2004-11-30 2011-11-10 Amgen Fremont Inc. Antibodies directed to GPNMB and uses thereof
US7947839B2 (en) 2004-12-01 2011-05-24 Genentech, Inc. Heterocyclic-substituted bis-1,8 naphthalimide compounds, antibody drug conjugates, and methods of use
EP1817059A2 (fr) 2004-12-01 2007-08-15 Genentech, Inc. Conjugues medicament anticorps et procedes correspondants
US20070134243A1 (en) 2004-12-01 2007-06-14 Gazzard Lewis J Antibody drug conjugates and methods
JP2008523001A (ja) 2004-12-13 2008-07-03 エフ．ホフマン−ラ ロシュ アーゲー ３−ピロリジン−２−イル−プロピオン酸誘導体を製造するための新規な方法
BRPI0518994A2 (pt) 2004-12-31 2008-12-02 Biogen Idec Inc anticorpos ou polipeptÍdeos que se ligam a br3, seus usos e formulaÇÕes lÍquidas
US7301019B2 (en) 2005-01-21 2007-11-27 Immunogen, Inc. Method for the preparation of maytansinoid esters
CA2594636A1 (fr) 2005-01-31 2006-08-10 Genentech, Inc. Anticorps anti-ephb2 et methodes d'utilisation associees
JP2008535823A (ja) 2005-03-25 2008-09-04 キュラジェン コーポレイション テネイシンの主要な抗原に対する抗体
NZ563370A (en) 2005-06-20 2010-10-29 Genentech Inc Compositions and methods for the diagnosis and treatment of tumor
NZ565075A (en) 2005-06-20 2011-05-27 Psma Dev Company Llc PSMA antibody-drug conjugates
US8871720B2 (en) 2005-07-07 2014-10-28 Seattle Genetics, Inc. Monomethylvaline compounds having phenylalanine carboxy modifications at the C-terminus
JP5171621B2 (ja) 2005-07-07 2013-03-27 シアトル ジェネティックス， インコーポレイテッド フェニルアラニン側鎖修飾をｃ末端に有するモノメチルバリン化合物
HUE035853T2 (en) 2005-07-18 2018-05-28 Seattle Genetics Inc Beta-glucuronide-linker-drug conjugates
WO2007021674A2 (fr) 2005-08-09 2007-02-22 Millennium Pharmaceuticals, Inc. Procede d'acylation de maytansinol a l'aide d'aminoacides chiraux
US20090304721A1 (en) 2005-09-07 2009-12-10 Medlmmune, Inc Toxin conjugated eph receptor antibodies
HRP20110498T1 (hr) 2005-10-07 2011-08-31 Exelixis Azetidini kao inhibitori mek za liječenje proliferativnih bolesti
EP1942944A2 (fr) 2005-10-31 2008-07-16 Genentech, Inc. Conjugués anticorps-médicaments à base de depsipeptide macrocyclique et méthodes associées
EP2548583A3 (fr) 2005-11-10 2013-02-27 Curagen Corporation Methode de traitement du cancer de l'ovaire et du rein utilisant des anticorps diriges contre l'antigene a domaine 1 de mucine et a domaine immunoglobuline des lymphocytes t (tim-1)
US20100040637A1 (en) 2005-11-23 2010-02-18 Karen Van Orden Methods and Composition for Treating Diseases Targeting Prominin-1 (CD133)
EP1954719A2 (fr) 2005-12-02 2008-08-13 Genentech Inc. Compositions et methodes de traitement de maladies et troubles associes e la signalisation de la cytokine
DOP2006000277A (es) 2005-12-12 2007-08-31 Bayer Pharmaceuticals Corp Anticuerpos anti mn y métodos para su utilización
US7750116B1 (en) 2006-02-18 2010-07-06 Seattle Genetics, Inc. Antibody drug conjugate metabolites
AR059900A1 (es) 2006-03-17 2008-05-07 Genentech Inc Anticuerpos anti-tat226 e inmunoconjugados
US8263038B2 (en) 2006-04-18 2012-09-11 Delta-Energy Holdings, Llc Method of devolatilizing recycled carbon black and associated method
ES2567402T3 (es) 2006-05-30 2016-04-22 Genentech, Inc. Anticuerpos anti CD22, sus inmunoconjugados y usos de los mismos
US9382327B2 (en) 2006-10-10 2016-07-05 Vaccinex, Inc. Anti-CD20 antibodies and methods of use
WO2008070593A2 (fr) 2006-12-01 2008-06-12 Seattle Genetics, Inc. Agents se liantà des cibles variables et utilisations de ceux-ci
DK2474557T3 (da) * 2007-07-16 2014-11-10 Genentech Inc Anti-CD79b-antistoffer og immunkonjugater og fremgangsmåder til anvendelse
NZ583318A (en) 2007-07-16 2012-07-27 Genentech Inc Humanized anti-cd79b antibodies and immunoconjugates and methods of use
CN101969970B (zh) 2007-10-12 2014-10-15 西雅图基因公司 用抗体-药物偶联物联合治疗
RU2476441C2 (ru) 2007-10-19 2013-02-27 Сиэтл Дженетикс, Инк. Cd19-связывающие средства и их применение
SG187517A1 (en) * 2008-01-31 2013-02-28 Genentech Inc Anti-cd79b antibodies and immunoconjugates and methods of use
US8742076B2 (en) 2008-02-01 2014-06-03 Genentech, Inc. Nemorubicin metabolite and analog reagents, antibody-drug conjugates and methods
TWI409079B (zh) 2009-08-14 2013-09-21 Roche Glycart Ag 非典型岩藻醣化ｃｄ２０抗體與苯達莫斯汀（ｂｅｎｄａｍｕｓｔｉｎｅ）之組合療法
WO2011038159A2 (fr) 2009-09-24 2011-03-31 Seattle Genetics, Inc. Conjugués ligand-médicament dr5
CN107898791A (zh) 2010-06-03 2018-04-13 药品循环有限责任公司 布鲁顿酪氨酸激酶(btk)抑制剂的应用
US20140030280A1 (en) 2012-07-09 2014-01-30 Genentech, Inc. Anti-cd79b antibodies and immunoconjugates
CN104768581A (zh) 2012-09-07 2015-07-08 吉宁特有限公司 II型抗CD20抗体与选择性Bcl-2抑制剂的组合治疗
WO2015084892A1 (fr) 2013-12-02 2015-06-11 Cornell University Méthodes de traitement des troubles de prolifération des lymphocytes b
US20140134405A1 (en) 2014-01-22 2014-05-15 Sung-Yun Yang Textile having an integral underlying layer of hook and loop fabric
PT3262071T (pt) 2014-09-23 2020-06-16 H Hoffnabb La Roche Ag Métodos de utilização de imunoconjugados anti-cd79b
MA40938A (fr) 2014-12-05 2017-10-11 Hoffmann La Roche Anticorps anti-cd79b et méthodes d'utilisation desdits anticorps
BR102016018430A2 (pt) 2016-08-10 2018-02-27 Fundação Oswaldo Cruz Cassete de expressão heteróloga, constructo de dna e composição vacinal para imunizar contra flavivírus e/ou outros patógenos.

Also Published As

Publication number Publication date
US10494432B2 (en) 2019-12-03
CO6270252A2 (es) 2011-04-20
EP2474557A3 (fr) 2012-12-26
EP2176296A1 (fr) 2010-04-21
USRE48558E1 (en) 2021-05-18
CA3065968A1 (fr) 2009-01-22
PH12020550741A1 (en) 2021-06-14
CY1112739T1 (el) 2016-02-10
HUS2000026I1 (hu) 2020-07-15
WO2009012268A1 (fr) 2009-01-22
CY2020021I2 (el) 2020-11-25
EP2474557B1 (fr) 2014-08-20
SI2176296T1 (sl) 2012-05-31
RU2013158986A (ru) 2015-07-10
FR20C1033I2 (fr) 2021-07-02
MY150531A (en) 2014-01-30
AU2008276140C1 (en) 2021-01-28
CY1115700T1 (el) 2017-01-25
HK1138855A1 (en) 2010-09-03
KR20120044383A (ko) 2012-05-07
CN103819560A (zh) 2014-05-28
EP2502937B1 (fr) 2016-04-06
IL219268A (en) 2015-02-26
ES2381788T3 (es) 2012-05-31
RU2010105232A (ru) 2011-08-27
AU2008276140B2 (en) 2012-04-12
CA3065968C (fr) 2022-08-09
AU2008276140A1 (en) 2009-01-22
CR20190516A (es) 2020-02-18
DK2176296T3 (da) 2012-05-21
HK1172046A1 (en) 2013-04-12
CA2693255C (fr) 2020-02-25
US20140099260A1 (en) 2014-04-10
US20200247887A1 (en) 2020-08-06
JP5723392B2 (ja) 2015-05-27
PL2474557T3 (pl) 2015-02-27
CN111499748A (zh) 2020-08-07
LTC2474557I2 (lt) 2021-12-10
IL233149A0 (en) 2014-07-31
ZA201000080B (en) 2012-09-26
RU2694688C3 (ru) 2021-11-16
US8691531B2 (en) 2014-04-08
JP2014122222A (ja) 2014-07-03
HRP20141114T1 (hr) 2015-01-30
NL301056I1 (nl) 2020-08-14
UA116618C2 (uk) 2018-04-25
RS53595B1 (sr) 2015-02-27
ECSP109878A (es) 2010-02-26
US8545850B2 (en) 2013-10-01
BRPI0812691B8 (pt) 2022-07-19
RU2019121267A (ru) 2021-01-12
EP2502937A2 (fr) 2012-09-26
CN101802012B (zh) 2014-08-06
JP2010533496A (ja) 2010-10-28
IL219268A0 (en) 2012-06-28
US20110135667A1 (en) 2011-06-09
TWI392503B (zh) 2013-04-11
US20220251197A1 (en) 2022-08-11
NL301056I2 (nl) 2020-08-13
PT2474557E (pt) 2014-12-03
TW200911285A (en) 2009-03-16
US20120148600A1 (en) 2012-06-14
PE20140614A1 (es) 2014-05-28
RU2694688C2 (ru) 2019-07-16
ES2522269T3 (es) 2014-11-14
SG183023A1 (en) 2012-08-30
AR067544A1 (es) 2009-10-14
PL2176296T3 (pl) 2012-07-31
SI2474557T1 (sl) 2014-12-31
CA2693255A1 (fr) 2009-01-22
CN106432496B (zh) 2020-02-07
PH12013501338A1 (en) 2016-01-25
EP2176296B1 (fr) 2012-02-01
FR20C1033I1 (fr) 2020-10-02
KR20100041833A (ko) 2010-04-22
RU2511410C3 (ru) 2021-06-15
US20190276550A9 (en) 2019-09-12
PT2176296E (pt) 2012-05-14
CR11274A (es) 2010-05-31
NZ602024A (en) 2014-04-30
BRPI0812691B1 (pt) 2022-06-21
EP2502937A3 (fr) 2013-03-20
JP5469600B2 (ja) 2014-04-16
NO2020020I1 (no) 2020-07-15
CN101802012A (zh) 2010-08-11
TW201235049A (en) 2012-09-01
RU2511410C2 (ru) 2014-04-10
CY2020021I1 (el) 2020-11-25
BR122022005321B1 (pt) 2022-08-16
US20090028856A1 (en) 2009-01-29
ES2579323T3 (es) 2016-08-09
NZ583367A (en) 2012-10-26
CN106432496A (zh) 2017-02-22
CR11216A (es) 2010-04-20
BRPI0812691A2 (pt) 2020-08-18
CL2008002085A1 (es) 2008-11-21
IL203142A (en) 2015-02-26
DK2474557T3 (da) 2014-11-10
CA3160831A1 (en) 2009-01-22
KR101486615B1 (ko) 2015-01-28
HK1197246A1 (en) 2015-01-09
US8088378B2 (en) 2012-01-03
TWI439286B (zh) 2014-06-01
JP2013136590A (ja) 2013-07-11
HRP20120352T1 (hr) 2012-05-31
LTPA2020523I1 (lt) 2020-08-10
SG10201509384PA (en) 2015-12-30
HK1171461A1 (en) 2013-03-28
PE20090943A1 (es) 2009-08-05
EP2474557A2 (fr) 2012-07-11
RS52305B (sr) 2012-12-31
ATE543835T1 (de) 2012-02-15
CN103819560B (zh) 2017-01-04

Similar Documents

Publication Publication Date Title
MA31606B1 (fr) Anticorps anti-cd 79b immunoconjugues et procedes d'utilisation
MA31605B1 (fr) Anticorps anti-cd79b humanisés, immunoconjugués, et procédés d'utilisation
MA31502B1 (fr) Anticorps anti-notch 1 specifiques a nrr et ses procedes d'utilisation
MA31231B1 (fr) Anticorps anti-robo4 et utilisations de ceux-ci
SG10201405377XA (en) Compositions and methods for antibodies targeting complement protein c5
MA29816B1 (fr) Composes de benzimidazole thiophene
MA33208B1 (fr) Anticorps anti-fgfr3 et procédés d'utilisation de ceux-ci
MA30910B1 (fr) Anticorps et immunoconjugues, et leurs utilisations
EA201300242A1 (ru) Фармацевтические композиции, содержащие замещенные ациланилиды
TN2010000068A1 (en) Anticorps anti-cd37
MY153198A (en) Inhibitors of protein aggregation
MA33197B1 (fr) Inhibiteurs de tripeptide époxy cétone protéases cristallines
CR11179A (es) Anticuerpos humanizados contra el globometro ab (20-42) y sus usos
MA30531B1 (fr) Anticorps anti-dll4 et leurs procedes d'utilisation
MA33256B1 (fr) Anticorps et immunoconjugués anti-fcrh5 et procédés d'utilisation
MA30153B1 (fr) Anticorps anti-ox40l et methodes correspondantes
MA32126B1 (fr) Anticorps et immunoconjugués anti-cd79b et leurs procédés d'utilisation
SG166813A1 (en) 5-lipoxygenase-activating protein (flap) inhibitors
TW200714283A (en) Method and composition for treating peripheral vascular diseases
MA30042B1 (fr) Composes calcilytiques
EA200901166A1 (ru) Соединения и композиции в качестве модуляторов активности gpr 119
MA30945B1 (fr) Anticorps anti-tat226 et immunoconjugués
MX2009000285A (es) Piperidinas sustituidas que incrementan la actividad de p53 y usos de las mismas.
EP1844077A4 (fr) Anticorps dr5 et utilisations de ceux-ci
EA017150B9 (ru) Ингибиторы белка, активирующего 5-липоксигеназу (flap)